New coronavirus variants could cause more reinfections, require updated vaccines

@article{Kupferschmidt2021NewCV,
  title={New coronavirus variants could cause more reinfections, require updated vaccines},
  author={Kai Kupferschmidt},
  journal={Science},
  year={2021}
}

VARIANTS OF COVID-19: WHAT DO WE NEED TO KNOW

The article describes the variants of COVID-19 and their classification, which is very important for better understanding and prevention of COVID-19 pandemic. Some variants spread more easily and

Initial Introduction and Spread of the SARS‐CoV‐2 AY.4.2.1 Delta Variant in Bulgaria, a Genomic Insight

Using genomic epidemiology, the first insights are provided of the introduction of AY.4.2.2 in Bulgaria and the A.3.1.1 sublineage that found larger dissemination only in the United Kingdom.

Whole-genome analysis and mutation pattern of SARS-CoV-2 during first and second wave outbreak in Gwangju, Republic of Korea

An in-depth analysis of SARS-COV-2 whole genome is provided which can shed light in the understanding of SIDS pathogenesis and mutation pattern which can aid in the development of prevention methods as well as future research into the pathogenesis of Sars-CoV- 2 and therapeutic development.

Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic

Preexisting antibodies can help the body protect against SARS-CoV-2 infection, reduce the severity of COVID-19, and rapidly increase the immune response post-infection.

Repeated vaccination and ‘vaccine exhaustion’: relevance to the COVID-19 crisis

A need to revisit the standard recommendations for influenza vaccination, which may prescribe 40 or more doses of influenza vaccine over a lifetime, is suggested, as the impact of repeated vaccination on effectiveness is not yet clearly defined.

COVID-19: vaccines, efficacy and effects on variants

Three leading strategies of vaccine development against coronavirus disease 2019 (COVID- 19): mRNA vaccines, adenoviral vector vaccines and recombinant nanoparticles are reviewed and the evidence for the effectiveness of the vaccines against those five VoC is explored.

Testing fractional doses of COVID-19 vaccines

There are high expected social returns to investigating the scope for lowering the dosage of some COVID-19 vaccines, and the existing evidence is presented and epidemiological models are used to quantify benefits under various scenarios.

SARS-CoV-2 Therapeutic Landscape, Opportunity and Future Threats

Developing a global viral, fungi and microbes platform can help to predict mutations on their genomic, structural and pathophysiological profile to better address early on future threats by such infectious agents.